Programmed Death-ligand 1 Expression With Clone 22C3 in Non-small Cell Lung Cancer: A Single Institution Experience

BACKGROUND: In recent years, the anti-programmed cell death 1 (PD-1) drug pembrolizumab (Keytruda) was approved for treatment of unresectable advanced non-small cell lung cancer (NSCLC) as first- or second-line therapy depending on the clone 22C3-programmed death-ligand 1 (PD-L1) immunohistochemical...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Med Insights Oncol
Asıl Yazarlar: Takeda, Maiko, Kasai, Takahiko, Naito, Maiko, Tamiya, Akihiro, Taniguchi, Yoshihiko, Saijo, Nobuhiko, Naoki, Yoko, Okishio, Kyoichi, Shimizu, Shigeki, Kojima, Kensuke, Nagoya, Akihiro, Sakamoto, Tetsuki, Utsumi, Tomoki, Yoon, Hyung-Eun, Matsumura, Akihide, Atagi, Shinji
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: SAGE Publications 2019
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6329032/
https://ncbi.nlm.nih.gov/pubmed/30670923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1179554918821314
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller